Results for end of TB therapy assessment compared with baseline for all those assessed at both time points, using the CPA categorisation at the second time point
| Symptoms | Early TB therapy (n=128) | End of therapy (n=128) | P value | CPA* (n=10) | non-CPA (n=118) | P value |
| Gender | ||||||
| Male | 52 (41%) | 52 (41%) | 5 (50%) | 47 (40%) | ||
| Female | 76 (59%) | 76 (59%) | – | 5 (50%) | 71 (60%) | 0.526 |
| Age (mean; range) | 38.3 (17–77) | 38.3 (17–77) | – | 52 (22–77) | 37.1 (17–72) | 0.004 |
| Symptoms (>3 months) | ||||||
| Cough | 22 (17%) | 18 (14%) | 0.556 | 5 (50%) | 13 (11%) | 0.005 |
| Fatigue | 9 (7%) | 21 (17%) | 0.031 | 6 (60%) | 15 (13%) | 0.001 |
| Dyspnoea | 7 (6%) | 16 (13%) | 0.064 | 3 (30%) | 13 (11%) | 0.111 |
| Chest pain | 6 (5%) | 7 (6%) | 1 | 2 (20%) | 5 (4%) | 0.094 |
| Weight loss | 5 (4%) | 3 (2%) | 0.727 | 0 | 3 (3%) | 1.000 |
| Haemoptysis | 3 (2%) | 3 (2%) | 0.727 | 1 (10%) | 2 (2%) | 0.218 |
| Intermittent haemoptysis (<3 months) | 24 (19%) | 3 (2%) | <0.001 | 1 (14%) | 2 (3%) | 0.286 |
| Radiology | ||||||
| Infiltrates | 123 (96%) | 102 (80%) | <0.001 | 8 (80%) | 94 (80%) | 1.000 |
| Cavitation | 67 (52%) | 45 (35%) | <0.001 | 7 (70%) | 38 (32%) | 0.033 |
| Paracavitary fibrosis | 43 (34%) | 28 (22%) | 0.001 | 4 (40%) | 24 (20%) | 0.224 |
| Pleural thickening | 32 (25%) | 31 (24%) | 1 | 5 (50%) | 26 (22%) | 0.061 |
| Nodules | 23 (18%) | 15 (12%) | 0.039 | 0 | 15 (13%) | 0.605 |
| Air fluid level in cavities | 21 (16%) | 4 (3%) | <0.001 | 1 (10%) | 3 (3%) | 0.281 |
| Aspergilloma† | 3 (2%) | 4 (3%) | 1 | 1 (10%) | 3 (3%) | 0.281 |
| Bronchiectasis | 8 (6%) | 13 (10%) | 0.125 | 1 (10%) | 12 (10%) | 1.000 |
Bold values indicate statistical significance.
*Proven CPA.
†One aspergilloma at baseline (non-CPA) was confirmed on CT scan, the rest were unconfirmed aspergilloma diagnosed on chest X-ray.
CPA, chronic pulmonary aspergillosis.